Aphranel

What Aphranel does

Aphranel is a China-origin regenerative medical aesthetics brand operating under Shanghai Moyang Biotechnology Co., Ltd. (上海摩漾生物科技有限公司), headquartered in Shanghai and founded in 2018. The company develops and commercializes Calcium Hydroxyapatite (CaHA) microsphere-based injectable facial fillers and skinboosters designed to combine immediate structural support with progressive collagen regeneration. Its proprietary technology stack centers on the ACD-MT® microsphere platform (uniform 30-35 micron raspberry-shaped porous particles delivering ~35 million microspheres per mL and up to 74% porosity) and the PCD-ETT® CMC gel carrier (chemical-crosslinker-free, ~5,500 Pa G' viscoelasticity, near-isosmotic to human tissue). The portfolio is protected by over 35 Chinese national and 6 international invention patents.

The commercial product portfolio is anchored by MagiCCrystal Novo as the flagship regenerative filler, with Aphranel Arc (launched May 2026) as the second flagship product and PurElsa CaHAbooster 6 and 8 as supporting skin regeneration SKUs. Aphranel runs a B2B go-to-market, selling exclusively through authorized medical aesthetics clinics and certified physicians with no direct-to-consumer channel. Within its first year (May 2025 to May 2026), the company scaled to 620+ clinic partnerships across 28 Chinese provinces and 94 cities, certified 700+ physicians, and delivered 150,000+ syringes. It layers on community and event-led channels including The Norns global physician program (Dialogue, Exchange, Convergence) and high-profile conference presence at IMCAS Paris 2026 and SAAM 2025 Riyadh to drive international expansion.

Revenue is generated from one-time product sales (B2B) at quote-based, non-publicly disclosed wholesale pricing structured around multi-year clinic contracts. Founder Lin Guangming, who previously held senior roles at Johnson & Johnson, Stryker, Zimmer Biomet, and WEGO, leads the company and has anchored R&D through participation in China's National 863 Program for absorbable biomaterials and the National Key R&D Program for Biomedical Materials and Tissue Regeneration. Aphranel holds China's first NMPA Class III approval for an original CaHA microsphere injectable facial filler (February 2025), the first EU MDR Class III certification for a China-originated injectable filler (May 2026), and Saudi SFDA Class D registration, giving it a regulatory-first-mover position versus Chinese peers seeking similar international approvals.

Name

Aphranel

Legal name

Shanghai Moyang Biotechnology Co., Ltd. (上海摩漾生物科技有限公司)

Website

https://aphranel.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Aphranel is a China-origin regenerative medical aesthetics brand under Shanghai Moyang Biotechnology that develops and sells CaHA microsphere injectable fillers and skinboosters to certified physicians and medical aesthetics clinics, using proprietary ACD-MT® and PCD-ETT® technologies protected by 35+ patents.

Ownership category

akta.pro rank

Product category

Medical Aesthetic Injectables

NAICS

Toilet Preparation Manufacturing (325620)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844), Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAKACAE

Cosmetic Dermatology (Aesthetic Injectables)

Healthcare & Life Sciences/Specialist Medical Practice/Dermatology

SECONDARYCRABALAF

Professional Skincare & Facial Treatments

Consumer Products & Retail/Beauty & Personal Care/Professional Salon & Spa Products

Keywords

• Regenerative aesthetics
• CaHA injectable fillers
• Medical aesthetics devices
• Biomaterial technology
• Facial contouring fillers

Headquarters

HQ city

Jiangyuan

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. CaHA Injectable Filler Product Sales: Revenue from sale of regenerative CaHA-based injectable facial fillers including Aphranel MagiCCrystal Novo and PurElsa CaHAbooster product lines. Product-based revenue model with direct sales to medical clinics and physicians.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Aphranel develops, manufactures, and sells regenerative Calcium Hydroxyapatite (CaHA) microsphere-based injectable facial fillers and skinboosters under the MagiCCrystal Novo, Aphranel Arc, and PurElsa CaHAbooster lines. Products are sold to licensed medical aesthetics clinics and physicians, who administer them to patients for facial structural contouring, volume restoration, and progressive collagen regeneration. The company is positioned as the first China-origin injectable facial filler to achieve EU MDR Class III certification.

Product overview

Aphranel is a China-origin regenerative medical aesthetics brand under Shanghai Moyang Biotechnology, specializing in CaHA (Calcium Hydroxyapatite) injectable fillers and skinboosters. The product portfolio centers on MagiCCrystal Novo as the primary structural filler, with Arc as the second flagship product. Supporting offerings include PurElsa CaHAbooster 6 and 8 for skin regeneration, and The Norns global physician engagement program. All products are built on proprietary ACD-MT microsphere technology and PCD-ETT gel technology, united by the 'Poetics of Time' philosophy emphasizing long-term aesthetic outcomes through immediate shaping, evolving regeneration, and controlled degradation.

Differentiator

Problem solved

Functional benefit

Brands

• MagiCCrystal: Regenerative CaHA-based injectable filler designed for structural contouring, collagen regeneration, and long-term aesthetic integration.
• MagiCCrystal Novo
• Aphranel Novo
• Aphranel Arc
• PurElsa CaHAbooster
• The Norns

Products and services

• Aphranel MagiCCrystal Novo Regenerative CaHA-based injectable facial filler designed for structural support, contour enhancement, and collagen regeneration. Combines 30% CaHA microspheres with 70% CMC gel carrier to deliver immediate structural support and progressive collagen stimulation; administered by licensed medical aesthetics clinics and physicians.
• Aphranel Arc Second flagship CaHA injectable filler designed for structural contouring and regeneration. Launched in May 2026 as a distinct major product offering for medical aesthetics clinics and physicians.
• PurElsa CaHAbooster 8 Regenerative CaHA skinbooster formulated for skin firming, fine-line improvement, and barrier anti-aging. Uses patented CaHA microspheres and modified Polysaccharide Cellulose (CMC) to support collagen regeneration and improve skin elasticity and texture for clinics and physicians.
• PurElsa CaHAbooster 6 Regenerative CaHA skinbooster formulated for brightening, hydration, and skin-barrier repair. Powered by patented CaHA microspheres and gradient modified Polysaccharide Cellulose (CMC) to improve dullness, redness, uneven texture, and sensitive skin conditions.
• The Norns Global Physician Program Global regenerative aesthetics engagement and education program for licensed physicians and clinics, supporting training, certification, clinical exchange, and ongoing professional development for users of Aphranel CaHA products.

Quantifiable outcome

• Over 150,000 syringes delivered within first year of operations
• +5 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and critical.

• European, Middle Eastern, and Asia-Pacific Medical InstitutionscoreStrategic or Co-development Partner · 20 May 2026Collaboration agreements signed across Europe, the Middle East, and the Asia-Pacific region as part of international expansion plans. Includes physician exchange programs, clinical collaboration, and academic partnerships through The Norns initiative.
• BSI (British Standards Institution)criticalImplementation/ SI/ Consulting Partner · 18 May 2026UK-based Notified Body BSI conducted the EU MDR certification process over 2 years and 7 months, reviewing over 6,381 pages of technical documentation. BSI confirmed compliance with EU regulatory requirements covering quality management, clinical evaluation, manufacturing standards, safety, and post-market surveillance.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Merz Aesthetics: Merz manufactures Radiesse, the established CaHA-based injectable filler that is the closest direct competitor to Aphranel's MagiCCrystal Novo. Both compete in regenerative/biostimulator facial aesthetics with similar clinical use cases.
• Evolus: Evolus commercializes Jeuveau (botulinum toxin) and is expanding into biostimulator aesthetics, sharing Aphranel's physician-channel, premium clinic positioning and recent-IPO commercialization playbook.
• Sinclair Pharma: Sinclair offers Ellansé (PCL/CMC biostimulator) and MaiLi HA fillers, directly overlapping with Aphranel's CaHA-plus-CMC regenerative positioning and premium clinic channel go-to-market.
• Teoxane Laboratories: Teoxane produces a premium HA filler range (Teosyal) sold through medical aesthetics clinics globally, competing with Aphranel for physician preference and clinic shelf space in structural facial contouring.
• Crown Laboratories (formerly Revance): Crown acquired Revance and its RHA resilient HA filler line plus the DAXXIFY neuromodulator, positioning it as a diversified aesthetics player competing with Aphranel across injectables categories.
• Galderma: Galderma markets Sculptra (PLLA biostimulator) alongside Restylane HA fillers, competing with Aphranel in the regenerative/collagen-stimulating aesthetics category across global medical aesthetics channels.

Broad incumbents

• AbbVie (Allergan Aesthetics): Allergan Aesthetics, now part of AbbVie, markets the Juvéderm HA filler family and dominates the global injectable aesthetics category; Aphranel competes for share of physician time and clinic formulary in the same medical aesthetics channel.
• LG Chem (Life Sciences): LG Chem's life sciences division produces HA-based dermal fillers (e.g., Yvoire) and is a major Asia-based aesthetics incumbent competing with Aphranel in Korean, Chinese, and SE Asian clinic channels.

Emerging players

• Hugel: Korean aesthetics and biostimulator company with growing international footprint; competes with Aphranel in Asian and emerging markets with HA fillers and botulinum toxin products.
• BioPlus Co., Ltd. Korean emerging aesthetics player focused on PDLLA and PLLA biostimulator fillers, overlapping with Aphranel's regenerative aesthetic positioning in the Asia-Pacific market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/aphranel_my

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aphranel